Clinuvel PharmaceuticalsASX:CUV +0.78%86 PS Ratio is 5.40 as of Jul. 07, 2026, which is 78% below its 10-year median of 24.11. GuruFocus rates ASX:CUV with a GF Score™ of 86/100 and a GF Value™ of A$17.74 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 929 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 64.91% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Clinuvel Pharmaceuticals's share price is A$10.29.
Clinuvel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.91. Hence, Clinuvel Pharmaceuticals's PS Ratio for today is 5.40.
The historical rank and industry rank for Clinuvel Pharmaceuticals's PS Ratio or its related term are showing as below:
ASX:CUV'
s PS Ratio Range Over the Past 10 Years
Min: 4.75 Med: 24.11 Max: 74.85
Current: 5.4
During the past 13 years, Clinuvel Pharmaceuticals's highest PS Ratio was 74.85. The lowest was 4.75. And the median was 24.11.
ASX:CUV's PS Ratio is ranked better than 64.91% of 929
companies
in the Biotechnology industry
Industry Median: 9.64
vs ASX:CUV: 5.40
Clinuvel Pharmaceuticals Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Clinuvel Pharmaceuticals was 5.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 14.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 23.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 35.70% per year.
During the past 13 years, Clinuvel Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 97.40% per year. The lowest was 14.10% per year. And the median was 29.65% per year.
Back to Basics: PS Ratio
Clinuvel Pharmaceuticals (ASX:CUV) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Clinuvel Pharmaceuticals's Share Price of today is A$10.29.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.91.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Clinuvel Pharmaceuticals (ASX:CUV) has a PS Ratio of 5.40 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 78% below median its historical median of 24.11. Over the past decade, Clinuvel Pharmaceuticals' PS Ratio has ranged from 4.75 to 74.85. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #326 out of 929 companies in the Biotechnology industry, placing it in the top 35.1%.
Is Clinuvel Pharmaceuticals' PS Ratio too high?
Clinuvel Pharmaceuticals' current PS Ratio of 5.40 is 78% below median its 10-year median of 24.11. Over the past 10 years, this metric has ranged from a low of 4.75 to a high of 74.85. The Biotechnology industry median PS Ratio is 9.64. Clinuvel Pharmaceuticals' value of 5.40 is 44% below this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #326 out of 929 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #326 out of 929 companies for PS Ratio. This puts Clinuvel Pharmaceuticals in the upper half of its industry. The industry median PS Ratio is 9.64. Clinuvel Pharmaceuticals' value of 5.40 is 44% below this benchmark. Historically, Clinuvel Pharmaceuticals' own PS Ratio has ranged from 4.75 to 74.85 over the past decade. While the company's 10-year median is 24.11 vs. the industry median of 9.64, Clinuvel Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current PS Ratio of 5.40 is 44% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current PS Ratio is 5.40, which is 78% below median its own 10-year median of 24.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.74, compared to a current price of A$10.29 — trading 42% below its estimated fair value. The current PS Ratio is 5.40, which is 78% below median its 10-year median of 24.11 and 44% below the Biotechnology industry median of 9.64. Clinuvel Pharmaceuticals' overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current PS Ratio is 5.40 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$10.29 is trading 42% below its estimated GF Value™ of A$17.74.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
PS Ratio: 5.40 (78% below median its 10-year median of 24.11)
GF Value™: A$17.74 vs. price of A$10.29 (42% below fair value)
Industry Position: 44% below the Biotechnology median (#326 of 929)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
86GF Score
Get the complete analysis for ASX:CUV
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
